FrancophonIA/ELRC3.0 huggingface dataset:
English: Cisplatin is administered as an intravenous infusion on day 1 at a dose of 50 mg/m2/day and following the topotecan dose.
Danish: Cisplatin administreres som intravenøs infusion på dag 1 med en dosis på 50 mg/m2legemsoverflade/dag, efter administration af topotecan.
English: The pharmacokinetics of topotecan after oral administration have been evaluated in cancer patients following doses of 1.2 to 3.1 mg/m2/day and 4 mg/m2/day administered daily for 5 days.
Danish: Farmakokinetikken af topotecan ved oral administration er vurderet hos cancerpatienter efter administration af 1,2-3,1 mg/m2/dag og 4 mg/m2/dag daglig i 5 dage.
English: In dose-finding studies involving 523 patients with relapsed ovarian cancer and 631 patients with relapsed small cell lung cancer, the dose-limiting toxicity of topotecan monotherapy was found to be haematological.
Danish: I studier til dosisbestemmelse omfattende 523 patienter med recidiverende ovariecancer og 631 patienter med recidiverende småcellet lungecancer var den dosisbegrænsende toksicitet af topotecan-monoterapi hæmatologisk.
English: Subsequent doses Topotecan should not be re-administered unless the neutrophil count is 1 x 10
Danish: Efterfølgende doser Efterfølgende doser af topotecan bør ikke gives, medmindre neutrofiltallet er  1 x 10
English: 9/l and/or a platelet count of 100 x 10
Danish: 9/l og/eller et trombocyttal på < 100 x 10
English: Hycamtin 1 mg capsules are pink and imprinted with “Hycamtin” and “1 mg”.
Danish: Hycamtin 1 mg kapsler er pink og præget med “Hycamtin” og “1 mg”.
English: When topotecan (0.75 mg/m2/day for 5 consecutive days) and cisplatin (60 mg/m2/day on day 1) were administered in 13 patients with ovarian cancer, a slight increase in AUC (12%, n = 9) and Cmax (23%, n = 11) was noted on day 5.
Danish: Ved administration af topotecan (0,75 mg/m legemsoverflade/dag i 5 sammenhængende dage) og cisplatin (60 mg/m legemsoverflade/dag på dag 1) til 13 patienter med ovariecancer, blev en svag stigning set i AUC (12 %, n = 9) og Cmax (23 %, n = 11) på dag 5.
English: • Inflammation and ulcers of the mouth, tongue or gums.
Danish: • Betændelse og sår i mund, på tunge eller gummer.
English: 0C after the first puncture of the vial.
Danish: oC efter, at hætteglasset er punkteret første gang.
English: However, there are insufficient data available to make a dose recommendation for this patient group.
Danish: Der er dog ikke en tilstrækkelig mængde data tilgængelig til at kunne give en anbefaling vedrørende dosering til denne patientgruppe.
English: Median survival in patients treated with oral topotecan plus BSC was 25.9 weeks (95% CI: 18.3, 31.6) compared to 13.9 weeks (95% CI: 11.1, 18.6) for patients receiving BSC alone (p = 0.0104).
Danish: Medianoverlevelsen hos patienter behandlet med oral topotecan plus BSC var 25,9 uger (95 % CI: 18,3; 31,6) sammenlignet med 13,9 uger (95 % CI: 11,1; 18,6) for patienter, der fik BSC alene (p = 0,0104).
English: Area under the curve increased approximately in proportion to the increase in dose.
Danish: Arealet under kurven (AUC) øges omtrent proportionalt med dosis.
English: Hypersensitivity reactions including rash, urticaria, angioedema and anaphylactic reactions have been reported rarely.
Danish: I sjældne tilfælde er der rapporteret overfølsomhedsreaktioner heriblandt udslæt, urticaria, angioødem og anafylaktiske reaktioner.
English: • Itching sensation.
Danish: • En kløende fornemmelse.
English: The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
Danish: Anti-tumor-aktiviteten af topotecan involverer hæmning af topoisomerase-I, et enzym tæt involveret i DNA-replikation, da den eliminerer den torsionale belastning, der opstår foran den bevægelige replikationsgaffel.
English: Method of administration
Danish: ADMINISTRATIONESMETODE
English: The signs and symptoms observed following overdose were consistent with the known undesirable events associated with topotecan (see section 4.8).
Danish: De tegn og symptomer der blev observeret efter overdosering var i overensstemmelse med de kendte bivirkninger forbundet med topotecan (se pkt.
English: As with other cytotoxic medicinal products, topotecan may cause foetal harm and therefore women of childbearing potential should be advised to avoid becoming pregnant during therapy with topotecan.
Danish: Som for andre cytostatika kan topotecan forårsage fosterskader, hvorfor kvinder i den fertile alder bør rådes til at undgå graviditet, mens de er i behandling med topotecan.
English: Very common side effects
Danish: Meget almindelige bivirkninger
English: The safety profile of topotecan when given in combination with cisplatin in the cervical cancer clinical studies is consistent with that seen with topotecan monotherapy.
Danish: Sikkerhedsprofilen fra kliniske studier med topotecan, givet i kombination med cisplatin mod cervixcancer, er i overensstemmelse med, hvad der er set ved topotecan-monoterapi.
English: Since the vial contains a 10% overage, the clear, reconstituted solution is yellow to yellow-green in colour and provides 1 mg of topotecan per ml.
Danish: Eftersom hætteglasset indeholder et overskud på 10 %, indeholder den klare rekonstituerede opløsning, hvis farve er gul til gulgrøn, 1 mg topotecan pr. ml.
English: The clear, reconstituted solution is yellow to yellow-green in colour and provides 1 mg of topotecan per ml.
Danish: Den klare, rekonstituerede opløsning er gul til gulgrøn og indeholder 1 mg topotecan pr. ml.
English: Initial dose The recommended dose of HYCAMTIN capsules is 2.3 mg/m body surface area per day administered for five consecutive days with a three-week interval between the start of each course.
Danish: Første dosis Den anbefalede dosis af HYCAMTIN kapsler er 2,3 mg/m legemsoverflade pr. dag administreret hver dag fem dage i træk, med et interval på tre uger mellem begyndelsen af hver serie.
English: Topotecan 0.75 mg/m on days 1-3, every 21 days
Danish: 0,75 mg/m på dag 13, hver 21. dag
English: • If you have any further questions, ask your doctor.
Danish: • Spørg lægen, hvis der er mere, du vil vide.
English: A small number of hepatically impaired patients (serum bilirubin between 1.5 and 10 mg/dl) were given intravenous topotecan at 1.5 mg/m2/day for five days every three weeks.
Danish: Et lille antal hepatisk svækkede patienter (serumbilirubin mellem 1,5 og 10 mg/dl) fik topotecan 1,5 mg/m2/dag intravenøst i fem dage hver tredje uge.
English: The total content of active substance in the vial provides 1 mg per ml of active substance when reconstituted as recommended (see Package Leaflet).
Danish: Det totale indhold af aktivt stof i hætteglasset giver 1 mg pr. ml af aktivt stof, når rekonstitutionen foretages som anbefalet (se indlægssedlen).
English: Neutropenic colitis, including fatal neutropenic colitis, has been reported to occur as a complication of topotecan-induced neutropenia (see section 4.4).
Danish: Neutropenisk colitis, herunder letal neutropenisk colitis, er set som en komplikation til topotecaninduceret neutropeni (se pkt.
English: Platelet transfusions were given in 4% of courses.
Danish: Der blev givet trombocyttransfusioner i 4 % af serierne.
English: 9/l) in 25% of patients (15% of courses).
Danish: 9/l) hos 25 % af patienterne (15 % af serierne).
English: The capsule(s) must be swallowed whole, and must not be chewed, crushed or divided.
Danish: Kapslerne skal sluges hele og må ikke tygges, knuses eller deles.
English: A Phase III study (Study 478) compared oral topotecan plus best supportive care (BSC) (n = 71) with BSC alone (n = 70) in patients who had relapsed following first-line therapy (median time to progression [TTP] from first-line therapy: 84 days for oral topotecan plus BSC, 90 days for BSC alone) and for whom re-treatment with intravenous chemotherapy was not considered appropriate.
Danish: I et fase III-studie (studie 478) blev oral topotecan plus best supportive care (BSC) (n = 71) sammenlignet med BSC alene (n = 70) hos patienter, som havde tilbagefald efter 1. linje-behandling (mediantid til progression [TTP] fra 1. linje-behandling: 84 dage for oral topotecan plus BSC, 90 dage for BSC alene) og for hvem gentagelse af behandling med intravenøs kemoterapi ikke var hensigtsmæssig.
English: Median time to onset of severe neutropenia was nine days and the median duration was seven days.
Danish: Mediantiden til indtræden af alvorlig neutropeni var ni dage, og medianvarigheden syv dage.
English: Shellac
Danish: Shellak
English: In 18% of courses with severe thrombocytopenia the duration was >7 days.
Danish: Under 18 % af serierne med alvorlig trombocytopeni var varigheden > 7 dage.
English: Moderate thrombocytopenia (Grade 3 - platelets between 10.0 and 50.0 x 10
Danish: Moderat trombocytopeni (grad 3 - trombocyttal mellem 10,0 og 50,0 x 10
English: If reconstitution is performed under strict aseptic conditions Hycamtin infusion may be completed within 12 hours at room temperature (or 24 hours if stored at 2-8oC).
Danish: Hvis rekonstitutionen foretages under strenge aseptiske forhold, bør Hycamtin infusionen afsluttes inden for 12 timer ved stuetemperatur (eller inden for 24 timer, hvis produktet opbevares ved 2-8 °C).
English: In clinical studies, topotecan was discontinued if the dose needed to be reduced below 1.5 mg/m 2/day.
Danish: I kliniske studier blev topotecan-behandlingen stoppet, hvis dosis var blevet reduceret til 1,5 mg/m 2/dag.
English: General disorders and administration site conditions Very common Pyrexia, asthenia, fatigue Common
Danish: Almene symptomer og reaktioner på administrationsstedet Meget almindelig Pyreksi, asteni, træthed Almindelig
English: When treating cervical cancer, Hycamtin is combined with another medicine called cisplatin.
Danish: Ved behandling af livmoderhalskræft gives Hycamtin sammen med et andet lægemiddelstof, der kaldes cisplatin.
English: Concentrated ammonia solution Potassium hydroxide
Danish: Ammoniakopløsning, koncentreret Kaliumhydroxid
English: Loperamide was administered to 13% of patients in 5% of courses.
Danish: Loperamid blev givet til 13 % af patienterne i 5 % af serierne.
English: In a comparative study of topotecan and paclitaxel in patients previously treated for ovarian carcinoma with platinum-based chemotherapy (n = 112 and 114, respectively), the response rate (95% CI) was 20.5% (13%, 28%) versus 14% (8%, 20%) and median time to progression 19 weeks versus 15 weeks (hazard ratio 0.7 [0.6, 1.0]), for topotecan and paclitaxel, respectively.
Danish: I et sammenlignende studie med topotecan og paclitaxel hos patienter tidligere behandlet for ovariecancer med platinbaseret kemoterapi (henholdsvis n = 112 og n = 114), var responsraten (95 % CI) 20,5 % (13 %, 28 %) versus 14 % (8 %, 20 %) og mediantiden til progression var 19 uger versus 15 uger (hazard ratio 0,7 0,6; 1,0) for henholdsvis topotecan og paclitaxel.
English: When given in combination with cisplatin (cisplatin day 1, topotecan days 1 to 5), the clearance of topotecan was reduced on day 5 compared to day 1 (19.1 l/h/m compared to 21.3 l/h/m
Danish: Ved administration i kombination med cisplatin (cisplatin dag 1, topotecan dag 1 til 5) blev topotecanclearance reduceret på dag 5 sammenlignet med dag 1 (19,1 l/time/m legemsoverflade sammenlignet med 21,3 l/time/m legemsoverflade [n = 9]) (se pkt.
English: Patients with prior cisplatin chemoradiotherapy Cisplatin Topotecan/Cisplatin
Danish: Patienter med forudgående cisplatin kemo/stråleterapi cisplatin topotecan/cisplatin
English: Overall, the Ndesmethyl metabolite contributed a mean of less than 6% (range 4-8%) of the total topotecan-related material accounted for in the urine and faeces.
Danish: Samlet set bidrog Ndesmetylmetabolitten i gennemsnit mindre end 6 % (interval 4-8 %) til det lægemiddelstofrelaterede materiale i urin og fæces, som der kunne redegøres for.
English: Mucosal inflammation
Danish: Slimhindeinflammation
English: Faecal elimination of total topotecan accounted for 33% while faecal elimination of N-desmethyl topotecan was 1.5%.
Danish: Fæcal eliminering af uomdannet topotecan udgjorde 33 %, mens fæcal eliminering af N-desmetyltopotecan var 1,5 %.
English: Following co-administration of the ABCB1 (P-gp) and ABCG2 (BCRP) inhibitor, elacridar (GF120918) at 100 to 1000 mg with oral topotecan, the AUC0-∞ of topotecan lactone and total topotecan increased approximately 2.5-fold (see section 4.5 for guidance).
Danish: Ved samtidig administration af ABCB1 (P-gp)- og ABCG2 (BCRP)-hæmmeren elacridar (GF120918) ved 100-1.000 mg med oral topotecan, steg AUC0-∞ for topotecanlakton og total-topotecan ca. 2,5 gange (se pkt.
English: Cyclosporin A (an inhibitor of ABCB1, ABCC1 [MRP-1], and CYP3A4) administered with oral topotecan increased topotecan AUC to approximately 2-2.5-fold of control.
Danish: Ciclosporin A (en hæmmer af ABCB1, ABCC1 [MRP-1] og CYP3A4) administreret samtidig med oral topotecan medførte en øget topotecan-AUC til ca. 2 til 2,5 gange kontrolgruppen.
English: Subsequent doses Topotecan should not be re-administered unless the neutrophil count is 1.5 x 10
Danish: Efterfølgende doser Efterfølgende doser af topotecan bør ikke gives, medmindre neutrofiltallet er  1,5 x 10
English: Severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils <1.5 x 10
Danish: Alvorlig knoglemarvssuppression allerede inden første serie indledes, defineret som et neutrofiltal på < 1,5 x 10
English: Topotecan is contraindicated during breast-feeding (see section 4.3).
Danish: Topotecan er kontraindiceret under amning (se pkt.
English: 9/l, the platelet count is 100 x 10
Danish: 9/l, trombocyt tallet er  100 x 10
English: Administration of oral cyclosporine A (15 mg/kg), an inhibitor of transporters ABCB1 (P-gp) and ABCC1 (MRP-1) as well as the metabolising enzyme CYP3A4, within 4 hours of oral topotecan increased the dose normalised AUC0-24h of topotecan lactone and total topotecan approximately 2.0and 2.5-fold, respectively (see section 4.5).
Danish: Oral administration af ciclosporin A (15 mg/kg), som er en hæmmer af transportørerne ABCB1 (P-gp) og ABCC1 (MRP-1) samt det metaboliserende enzym CYP3A4, indenfor 4 timer efter oral topotecan, forøgede den dosisnormaliserede AUC0-24t ca. 2,0 og 2,5 gange for henholdsvis topotecanlakton og total-topotecan (se pkt.
English: Overall, the N-desmethyl metabolite contributed a mean of less than 7% (range 4-9%) of the total topotecan-related material accounted for in the urine and faeces.
Danish: Samlet set bidrog Ndesmethylmetabolitten i gennemsnit mindre end 7 % (interval 4-9 %) til det topotecan-relaterede materiale i urin og fæces, som der kunne gøres rede for.
English: An O-glucuronidation metabolite of topotecan and N-desmethyl topotecan has been identified in the urine.
Danish: En O-glukuroniseret metabolit af topotecan og Ndesmethyltopotecan er identificeret i urin.
English: Approximately 20% was excreted as total topotecan and 2% was excreted as N-desmethyl topotecan in the urine.
Danish: Ca. 20 % blev udskilt som uomdannet topotecan og 2 % blev udskilt som N-desmetyltopotecan i urinen.
English: • the disease being treated.
Danish: • din sygdom.
English: In 46% of courses with moderate to severe anaemia, the duration was >7 days.
Danish: I 46 % af serierne med moderat til alvorlig anæmi var varigheden > 7 dage.
English: Erythropoietin was administered to 10% of patients in 8% of courses.
Danish: Erytropoietin blev givet til 10 % af patienterne i 8 % af serierne.
English: There are insufficient data available with HYCAMTIN capsules to make a dose recommendation for this patient group (see section 4.4).
Danish: Der findes ikke tilstrækkelige data for HYCAMTIN kapsler til at kunne give doseringsrekommandationer for denne patientgruppe (se pkt.
English: O-glucuronides of both topotecan and N-desmethyl topotecan have been identified in the urine.
Danish: O-glukuronider af både topotecan og Ndesmetyltopotecan er fundet i urinen.
English: Type I flint glass vial with grey butyl rubber stopper and aluminium seal with plastic flip-off cap containing 1 mg of topotecan.
Danish: Hætteglas af type I flintglas med grå butylgummiprop og aluminiumsforsegling med plastik flip-off låg indeholdende 1 mg topotecan.
English: How Hycamtin is used
Danish: Sådan bruges Hycamtin
English: • if you plan to father a child. See section “Pregnancy and breast-feeding” below.
Danish: Se afsnittet ”Graviditet og amning” nedenfor.
English: Dosing recommendations for patients receiving oral topotecan with creatinine clearance less than 30 ml/min have not been established.
Danish: Der er ikke fastlagt en rekommandation for dosering til patienter, der får oral topotecan og har kreatinin-clearance under 30 ml/min.
English: The capsules are opaque, pink and imprinted with “HYCAMTIN” and “1 mg”.
Danish: Kapslerne er uigennemsigtige lyserøde og præget med “HYCAMTIN” og “1 mg”.
English: • Swelling caused by fluid build-up (angioedema).
Danish: • Hævelser under hud eller slimhinder forårsaget af væskeophobning (angioødemer).
English: The recommended dose of topotecan is 1.5 mg/m body surface area per day administered by intravenous infusion over 30 minutes daily for five consecutive days with a three-week interval between the start of each course.
Danish: Den anbefalede dosis af topotecan er 1,5 mg/m legemsoverflade pr. dag administreret som intravenøs infusion over 30 minutter hver dag fem dage i træk, med et interval på tre uger mellem begyndelsen af hver serie.
English: Type I flint glass vial, with grey butyl rubber stopper and aluminium seal with plastic flip-off cap containing 4 mg of topotecan.
Danish: Hætteglas af type I flintglas med grå butylgummiprop og aluminiumsforsegling med plastik flip-off låg indeholdende 4 mg topotecan.
English: 1.25 mg/m 2/day (or subsequently down to 1.0 mg/m 2/day if necessary).
Danish: (eller derefter om nødvendigt ned til 1,0 mg/m 2/dag).
English: The recommended monotherapy dose of topotecan in patients with ovarian or small cell lung carcinoma and a creatinine clearance between 20 and 39 ml/min is 0.75 mg/m2/day for five consecutive days.
Danish: Den rekommanderede topotecandosis ved monoterapi hos patienter med ovariecancer eller småcellet lungecancer og en kreatinin-clearance mellem 20 og 39 ml/min er 0,75 mg/m2/dag i fem sammenhængende dage.
English: Gastrointestinal perforation Hepatobiliary disorders Common
Danish: Gastrointestinal perforation Lever- og galdeveje Almindelig
English: Black iron oxide (E172)
Danish: Sort jernoxid (E172)
English: The appropriate volume of the reconstituted solution should be diluted with either 0.9 % w/v sodium chloride intravenous infusion or 5 % w/v glucose intravenous infusion, to a final concentration of between 25 and 50 microgram per ml.
Danish: Det passende volumen af den rekonstituerede opløsning bør fortyndes med enten 0,9 % w/v natriumchloridinfusionsvæske eller 5 % w/v glucoseinfusionsvæske til en endelig koncentration mellem 25 og 50 mikrogram pr. ml.
English: 9/l) for seven days or more or severe neutropenia associated with fever or infection, or who have had treatment delayed due to neutropenia, the dose should be reduced by 20% to 0.60 mg/m 2/day for subsequent courses (or subsequently down to 0.45 mg/m 2/day if necessary).
Danish: 9/l) i syv dage eller mere, eller alvorlig neutropeni forbundet med feber eller infektion, eller hvis behandling er blevet udskudt på grund af neutropeni, bør dosis reduceres med 20 % til 0,60 mg/m 2/dag i de efterfølgende serier (eller derefter om nødvendigt ned til 0,45 mg/m 2/dag).
English: Severe (Grade 3 or 4) fatigue and asthenia both occurred with an incidence of 3%.
Danish: Hyppigheden af alvorlig (grad 3 eller 4) træthed og asteni var i begge tilfælde 3 %.
English: • Weight loss and loss of appetite (anorexia); tiredness; weakness.
Danish: • Vægttab og appetitløshed, udmattelse (træthed), slaphed.
English: Platelet transfusions were given to 10% of patients in 4% of courses.
Danish: Der blev givet trombocyttransfusioner til 10 % af patienterne i 4 % af serierne.
English: Interstitial lung disease (some cases have been fatal) Gastrointestinal disorders Very common Nausea, vomiting and diarrhoea (all of which may be severe), which may lead to dehydration (see sections 4.2 and 4.4)
Danish: Interstitiel lungesygdom (nogle tilfælde har været letale) Mave-tarm-kanalen Meget almindelig Kvalme, opkastning og diarré (alle muligvis alvorlige), der kan føre til dehydrering (se pkt.
English: Cervical carcinoma
Danish: Cervixcancer
English: The frequencies associated with the haematological and non-haematological adverse events presented are for adverse events considered to be related/possibly related to oral topotecan therapy.
Danish: De nævnte hyppigheder for hæmatologiske og non-hæmatologiske bivirkninger er for de bivirkninger, der anses for at have en sammenhæng eller en mulig sammenhæng med behandling med oral topotecan.
English: The capsules are opaque, white to yellowish white and imprinted with “HYCAMTIN” and “0.25 mg”.
Danish: Kapslerne er uigennemsigtige hvide til gullig-hvide og præget med “HYCAMTIN” og “0.25 mg”.
English: Results of a cross-study analysis suggest that the exposure to topotecan lactone, the active moiety following topotecan administration, increases with decreased renal function.
Danish: Krydsanalyse af studiedata tyder på, at eksponeringen for topotecanlacton, den aktive komponent, er højere hos patienter med nedsat nyrefunktion.
English: 9/l) occurred in 32% of patients in 13% of courses.
Danish: 9/l) sås hos 32 % af patienterne i 13 % af serierne.
English: There is insufficient experience with the use of topotecan in patients with severely impaired renal function (creatinine clearance <20 ml/min).
Danish: Der er utilstrækkelig erfaring med anvendelsen af topotecan hos patienter med alvorligt nedsat nyrefunktion (kreatininclearance <20 ml/min).
English: A major route of clearance of topotecan is by hydrolysis of the lactone ring to form the ring-opened carboxylate.
Danish: En vigtig eliminationsvej for topotecan er hydrolyse af laktonringen, så der dannes ringåbnet carboxylat.
English: • Stomach pain, constipation, indigestion.
Danish: • Mavesmerter, forstoppelse, fordøjelsesbesvær.
English: The cellular sequela of inhibition of topoisomerase-I by topotecan is the induction of protein-associated DNA single-strand breaks.
Danish: Den cellulære følge af topotecans hæmning af topoisomerase-I skyldes proteinassocierede enkelstrengsbrud på DNA.
English: Median time to onset of severe thrombocytopenia was day 15 and the median duration was five days.
Danish: Mediantiden før indtræden af alvorlig trombocytopeni var dag 15, og medianvarigheden var fem dage.
English: Further dilution of the appropriate volume of the reconstituted solution with either sodium chloride 9 mg/ml (0.9%) or 5% w/v glucose is required to give a final concentration of between 25 and 50 microgram/ml.
Danish: Yderligere fortynding af den rekonstituerede opløsning med enten natriumchlorid 9 mg/ml (0,9 %) eller 5 % w/v glucose er påkrævet for at opnå en endelig koncentration på mellem 25 og 50 mikrogram/ml.
English: Median time to onset of severe thrombocytopenia was day 15 with a median duration of 2.5 days.
Danish: Mediantiden til indtræden af alvorlig trombocytopeni var dag 15 med en medianvarighed på 2,5 dage.
English: Each capsule contains topotecan hydrochloride equivalent to 1 mg of topotecan.
Danish: Hver kapsel indeholder topotecanhydrochlorid svarende til 1 mg topotecan.
English: Neutropenia Severe neutropenia (Grade 4 - neutrophil count <0.5 x 10
Danish: Neutropeni Alvorlig neutropeni (grad 4 - neutrofiltal < 0,5 x 10
English: In this study, forty-six (43%) patients received G-CSF over 192 (42.1%) courses; sixty-five (60%) received transfusions of packed red blood cells and fifty (46%) of platelets over 139 and 159 courses (30.5% and 34.9%), respectively.
Danish: 65 patienter (60 %) fik transfusion af pakket blod, og 50 patienter (46 %) fik transfusion af trombocytter henholdsvis over 139 og 159 serier (henholdsvis 30,5 % og 34,9 %).